Takeda Pharmaceutical
Latest statistics and disclosures from Takeda Pharmaceutical's latest quarterly 13F-HR filing:
- Top 5 stock holdings are OVID, EQ, Xilio Therapeutics, STTK, Lyell Immunopharma, and represent 96.33% of Takeda Pharmaceutical's stock portfolio.
- Added to shares of these 1 stock: Lyell Immunopharma.
- Reduced shares in these 3 stocks: Hillevax (-$13M), TSBX, THRD.
- Sold out of its positions in Hillevax, THRD, TSBX.
- Takeda Pharmaceutical was a net seller of stock by $-14M.
- Takeda Pharmaceutical has $16M in assets under management (AUM), dropping by -16.29%.
- Central Index Key (CIK): 0001395064
Tip: Access up to 7 years of quarterly data
Positions held by Takeda Pharmaceutical consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Takeda Pharmaceutical
Takeda Pharmaceutical holds 8 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ovid Therapeutics (OVID) | 59.8 | $9.8M | 7.5M | 1.30 |
|
|
| Equillium (EQ) | 15.9 | $2.6M | 1.8M | 1.43 |
|
|
| Xilio Therapeutics | 7.6 | $1.2M | 1.5M | 0.84 |
|
|
| Shattuck Labs (STTK) | 7.5 | $1.2M | 516k | 2.39 |
|
|
| Lyell Immunopharma | 5.4 | $891k | +33% | 55k | 16.24 |
|
| American Well Corp-class A (AMWL) | 2.9 | $478k | 78k | 6.15 |
|
|
| Rani Therapeutics Hldgs (RANI) | 0.6 | $102k | 203k | 0.50 |
|
|
| D Fluidigm Corp Del (LAB) | 0.1 | $22k | 17k | 1.30 |
|
Past Filings by Takeda Pharmaceutical
SEC 13F filings are viewable for Takeda Pharmaceutical going back to 2025
- Takeda Pharmaceutical 2025 Q3 filed Nov. 13, 2025
- Takeda Pharmaceutical 2025 Q2 filed Aug. 8, 2025
- Takeda Pharmaceutical 2025 Q1 filed May 12, 2025